WO2022267936A1 - Anticorps spécifiquement lié à ceacam5 glycosylé - Google Patents
Anticorps spécifiquement lié à ceacam5 glycosylé Download PDFInfo
- Publication number
- WO2022267936A1 WO2022267936A1 PCT/CN2022/098746 CN2022098746W WO2022267936A1 WO 2022267936 A1 WO2022267936 A1 WO 2022267936A1 CN 2022098746 W CN2022098746 W CN 2022098746W WO 2022267936 A1 WO2022267936 A1 WO 2022267936A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- seq
- amino acid
- antigen
- deletions
- Prior art date
Links
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims abstract description 96
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims abstract description 22
- 238000002360 preparation method Methods 0.000 claims abstract description 10
- 238000006467 substitution reaction Methods 0.000 claims description 94
- 230000027455 binding Effects 0.000 claims description 93
- 238000009739 binding Methods 0.000 claims description 93
- 239000000427 antigen Substances 0.000 claims description 91
- 102000036639 antigens Human genes 0.000 claims description 90
- 108091007433 antigens Proteins 0.000 claims description 90
- 210000004027 cell Anatomy 0.000 claims description 88
- 238000012217 deletion Methods 0.000 claims description 84
- 230000037430 deletion Effects 0.000 claims description 84
- 238000007792 addition Methods 0.000 claims description 82
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 70
- 239000012634 fragment Substances 0.000 claims description 50
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 28
- 150000001413 amino acids Chemical group 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 21
- 206010028980 Neoplasm Diseases 0.000 claims description 19
- 229940079593 drug Drugs 0.000 claims description 19
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 19
- 230000014509 gene expression Effects 0.000 claims description 17
- 229920001184 polypeptide Polymers 0.000 claims description 16
- 108060003951 Immunoglobulin Proteins 0.000 claims description 15
- 102000018358 immunoglobulin Human genes 0.000 claims description 15
- 150000007523 nucleic acids Chemical class 0.000 claims description 15
- 108020004707 nucleic acids Proteins 0.000 claims description 14
- 102000039446 nucleic acids Human genes 0.000 claims description 14
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 12
- 210000004881 tumor cell Anatomy 0.000 claims description 12
- 239000013598 vector Substances 0.000 claims description 11
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 206010009944 Colon cancer Diseases 0.000 claims description 8
- 230000000259 anti-tumor effect Effects 0.000 claims description 8
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 7
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 6
- 239000013543 active substance Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- -1 radiosensitizers Substances 0.000 claims description 6
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 5
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 5
- 239000000611 antibody drug conjugate Substances 0.000 claims description 5
- 229940049595 antibody-drug conjugate Drugs 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 201000004101 esophageal cancer Diseases 0.000 claims description 5
- 206010017758 gastric cancer Diseases 0.000 claims description 5
- 201000011549 stomach cancer Diseases 0.000 claims description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 4
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 claims description 4
- BLUGYPPOFIHFJS-UUFHNPECSA-N (2s)-n-[(2s)-1-[[(3r,4s,5s)-3-methoxy-1-[(2s)-2-[(1r,2r)-1-methoxy-2-methyl-3-oxo-3-[[(1s)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-3-methyl-2-(methylamino)butanamid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 BLUGYPPOFIHFJS-UUFHNPECSA-N 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 4
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 4
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 229940100198 alkylating agent Drugs 0.000 claims description 4
- 239000002168 alkylating agent Substances 0.000 claims description 4
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 230000000340 anti-metabolite Effects 0.000 claims description 4
- 229940088710 antibiotic agent Drugs 0.000 claims description 4
- 229940100197 antimetabolite Drugs 0.000 claims description 4
- 239000002256 antimetabolite Substances 0.000 claims description 4
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims description 4
- 239000012642 immune effector Substances 0.000 claims description 4
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 4
- 229940121354 immunomodulator Drugs 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 230000000394 mitotic effect Effects 0.000 claims description 4
- 108010059074 monomethylauristatin F Proteins 0.000 claims description 4
- 244000309459 oncolytic virus Species 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 230000002285 radioactive effect Effects 0.000 claims description 4
- 108020003175 receptors Proteins 0.000 claims description 4
- 102000005962 receptors Human genes 0.000 claims description 4
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims description 4
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims description 4
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 4
- 241001529936 Murinae Species 0.000 claims description 3
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 2
- 230000000118 anti-neoplastic effect Effects 0.000 claims description 2
- 229960002685 biotin Drugs 0.000 claims description 2
- 235000020958 biotin Nutrition 0.000 claims description 2
- 239000011616 biotin Substances 0.000 claims description 2
- 229930195731 calicheamicin Natural products 0.000 claims description 2
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 239000000539 dimer Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000007850 fluorescent dye Substances 0.000 claims description 2
- 238000001415 gene therapy Methods 0.000 claims description 2
- 238000001794 hormone therapy Methods 0.000 claims description 2
- 229940127121 immunoconjugate Drugs 0.000 claims description 2
- 238000009169 immunotherapy Methods 0.000 claims description 2
- 230000002147 killing effect Effects 0.000 claims description 2
- 210000000822 natural killer cell Anatomy 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 238000009116 palliative therapy Methods 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 238000002626 targeted therapy Methods 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- 230000004614 tumor growth Effects 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 239000000243 solution Substances 0.000 description 32
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 24
- 108090000623 proteins and genes Proteins 0.000 description 24
- 210000004408 hybridoma Anatomy 0.000 description 22
- 102000004169 proteins and genes Human genes 0.000 description 17
- 206010035226 Plasma cell myeloma Diseases 0.000 description 12
- 201000000050 myeloid neoplasm Diseases 0.000 description 12
- 108091069214 CEA family Proteins 0.000 description 10
- 102000039968 CEA family Human genes 0.000 description 9
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 9
- 239000002671 adjuvant Substances 0.000 description 8
- 230000002163 immunogen Effects 0.000 description 8
- 238000012216 screening Methods 0.000 description 8
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 7
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 7
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 108091027544 Subgenomic mRNA Proteins 0.000 description 6
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 206010003445 Ascites Diseases 0.000 description 5
- 102100025470 Carcinoembryonic antigen-related cell adhesion molecule 8 Human genes 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 101000914320 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 8 Proteins 0.000 description 5
- 239000012980 RPMI-1640 medium Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 108010062802 CD66 antigens Proteins 0.000 description 4
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 description 4
- 102100025473 Carcinoembryonic antigen-related cell adhesion molecule 6 Human genes 0.000 description 4
- 102000014914 Carrier Proteins Human genes 0.000 description 4
- 108010078791 Carrier Proteins Proteins 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 101000914326 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 6 Proteins 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000003127 radioimmunoassay Methods 0.000 description 4
- 102100025466 Carcinoembryonic antigen-related cell adhesion molecule 3 Human genes 0.000 description 3
- 101000914337 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 3 Proteins 0.000 description 3
- 241000341655 Human papillomavirus type 16 Species 0.000 description 3
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 3
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000012202 endocytosis Effects 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 108091033409 CRISPR Proteins 0.000 description 2
- 238000010354 CRISPR gene editing Methods 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 101710162629 Trypsin inhibitor Proteins 0.000 description 2
- 229940122618 Trypsin inhibitor Drugs 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000012930 cell culture fluid Substances 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 239000003593 chromogenic compound Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 239000002753 trypsin inhibitor Substances 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 101150030298 CEACAM5 gene Proteins 0.000 description 1
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
- 102100035445 Carcinoembryonic antigen-related cell adhesion molecule 16 Human genes 0.000 description 1
- 102100035440 Carcinoembryonic antigen-related cell adhesion molecule 18 Human genes 0.000 description 1
- 102100035439 Carcinoembryonic antigen-related cell adhesion molecule 19 Human genes 0.000 description 1
- 102100024530 Carcinoembryonic antigen-related cell adhesion molecule 20 Human genes 0.000 description 1
- 102100024531 Carcinoembryonic antigen-related cell adhesion molecule 21 Human genes 0.000 description 1
- 102100025472 Carcinoembryonic antigen-related cell adhesion molecule 4 Human genes 0.000 description 1
- 101710190849 Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 1
- 102100025474 Carcinoembryonic antigen-related cell adhesion molecule 7 Human genes 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000737645 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 16 Proteins 0.000 description 1
- 101000737663 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 18 Proteins 0.000 description 1
- 101000737655 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 19 Proteins 0.000 description 1
- 101000981108 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 20 Proteins 0.000 description 1
- 101000981110 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 21 Proteins 0.000 description 1
- 101000914325 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 4 Proteins 0.000 description 1
- 101710157639 Minor capsid protein Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 101710136297 Protein VP2 Proteins 0.000 description 1
- 241000150264 Puumala orthohantavirus Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108010015780 Viral Core Proteins Proteins 0.000 description 1
- 241001492404 Woodchuck hepatitis virus Species 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 238000013357 binding ELISA Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000007771 core particle Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 108010093470 monomethyl auristatin E Proteins 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000003375 selectivity assay Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000003741 urothelium Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6853—Carcino-embryonic antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Definitions
- the present invention relates to antibodies. More specifically, this application relates to the preparation and application of a monoclonal antibody specifically binding to glycosylated CEACAM5, and its humanized antibody.
- CEA antigen (CEACAM5) in human colon cancer tissue extracts, and then detected free CEA antigen in the peripheral blood of patients with colorectal cancer and other cancers.
- CEA antigen is widely involved in cell adhesion, cell differentiation, cell proliferation and cell survival.
- CEA antigen is widely and highly expressed in digestive tract cancers, such as colorectal cancer, esophageal cancer, gastric cancer, etc. It has been used as a tumor marker for decades.
- CEACAM5 (CD66e, Carcinoembryonic antigen related cell adhesion molecule 5) is a carcinoembryonic antigen belonging to the CEA family.
- the CEA family includes 12 genes, all of which are located on chromosome 19q13;
- CEACAM5 is the gene with the largest molecular weight in the CEA family, expressed in the cell membrane (GPI anchor) and will be shed into the peripheral blood to become free CEA; it consists of 702 amino acids (N- A1-B1-A2-B2-A3-B3 domains in tandem), with a molecular weight of about 77KDa; the recombinantly expressed or purified CEACAM5 protein in ascites of colorectal cancer patients has a molecular weight of about 180KDa, indicating that CEACAM5 is highly glycosylated in cells.
- CEA family antigens exist in three forms: transmembrane, GPI-anchored and secreted, and their extracellular domains are composed of immunoglobulin domains.
- the extracellular region includes N-terminal domain, A1-3 domain and B1-3 domain formed in series.
- CEACAM1, CEACAM5, CEACAM6, CEACAM7, CEACAM8, CEACAM18, CEACAM20, and CEACAM21 contain N-terminal and AB domains;
- CEACAM3, CEACAM4, and CEACAM19 only contain N-terminal domains;
- CEACAM16 is a secreted protein.
- CEACAM family proteins, such as CEACAM1, CEACAM3, CEACAM5, CEACAM6, and CEACAM8 have high homology, and their tissue distribution is different.
- CEACAM1 is mainly distributed in urothelium and intestinal epithelium
- CEACAM6 is mainly distributed in alveoli and bile ducts
- CEACAM8 is mainly distributed in Bone marrow and hematopoietic system.
- CEACAM5 is widely and highly expressed in many cancers, such as digestive tract cancer (colorectal cancer, gastric cancer, pancreatic cancer, esophageal cancer), lung cancer, breast cancer, etc., and is an ideal tumor-associated antigen target (TAA, Tumor Associated Antigen).
- TAA tumor-associated antigen target
- the development of drugs targeting CEACAM5 is mainly concentrated in the field of antibody discovery, and the sequence homology of the CEA family is relatively high. Therefore, screening specific CEACAM5-targeting antibodies may reduce side effects in clinical use, thereby increasing the therapeutic window and improving drug efficacy.
- the invention provides a humanized antibody specifically binding to CEACAM5, which can be applied to the treatment of tumors with high expression of CEACAM5.
- One aspect of the present invention provides a monoclonal antibody antibody or antigen-binding fragment thereof against CEACAM5, which specifically binds to the N-A1-B1 domain of CEACAM5 and does not bind to A2-B2 and A3-B3 domain.
- a monoclonal antibody of the invention comprises a heavy chain variable region and a light chain variable region, wherein:
- the heavy chain variable region comprises: CDR-H1 shown in SEQ ID NO: 1 or a substitution, deletion or addition of one or several amino acids thereto (for example, 1, 2 or 3 amino acids Substitution, deletion or addition) sequence, CDR-H2 shown in SEQ ID NO: 2 or has one or several amino acid substitutions, deletions or additions (such as 1, 2 or 3 amino acids compared thereto) substitution, deletion or addition), and CDR-H3 shown in SEQ ID NO: 3 or has one or several amino acid substitutions, deletions or additions (such as 1, 2 or 3 amino acids) compared therewith.
- the light chain variable region comprises: CDR-L1 shown in SEQ ID NO: 4 or a substitution, deletion or addition of one or several amino acids compared thereto (such as 1 A, 2 or 3 amino acid substitutions, deletions or additions) sequence, CDR-L2 shown in SEQ ID NO: 5 or with one or several amino acid substitutions, deletions or additions (such as 1 , 2 or 3 amino acid substitutions, deletions or additions), and the CDR-L3 shown in SEQ ID NO: 6 or with one or several amino acid substitutions, deletions or additions (such as 1 , 2 or 3 amino acid substitutions, deletions or additions); or
- the heavy chain variable region comprises: CDR-H1 shown in SEQ ID NO: 7 or a substitution, deletion or addition of one or several amino acids thereto (for example, 1, 2 or 3 amino acids substitution, deletion or addition), the sequence of CDR-H2 shown in SEQ ID NO: 8, or a substitution, deletion or addition of one or several amino acids compared thereto (such as 1, 2 or 3 amino acids) substitution, deletion or addition), and the CDR-H3 shown in SEQ ID NO: 9 or has one or several amino acid substitutions, deletions or additions (such as 1, 2 or 3 amino acids compared thereto) Substitution, deletion or addition) sequence; at the same time, the light chain variable region comprises: CDR-L1 shown by SEQ ID NO: 10 or a substitution, deletion or addition of one or several amino acids compared thereto (such as 1 a, 2 or 3 amino acid substitutions, deletions or additions), the CDR-L2 shown in SEQ ID NO: 11 or therewith one or several amino acid substitutions, deletions or additions (such as
- the monoclonal antibody of the present invention comprises a heavy chain variable region and a light chain variable region, wherein:
- the heavy chain variable region comprises the polypeptide shown in SEQ ID NO: 13 or has one or several amino acid substitutions, deletions or additions thereto (such as 1, 2 or 3 amino acid substitutions, deletions) or addition), while the light chain variable region comprises the polypeptide shown in SEQ ID NO: 14 or has one or several amino acid substitutions, deletions or additions (for example, 1, 2 or 3 amino acid substitutions, deletions or additions); or
- the heavy chain variable region comprises the polypeptide shown in SEQ ID NO: 15 or has one or several amino acid substitutions, deletions or additions thereto (such as 1, 2 or 3 amino acid substitutions, deletions) or addition), while the light chain variable region comprises the polypeptide shown in SEQ ID NO: 16 or has one or several amino acid substitutions, deletions or additions (for example, 1, 2 or 3 amino acid substitutions, deletions or additions).
- substitution described in any one of said SEQ ID NO: 1-12 is a conservative substitution
- the CDRs of any one of said SEQ ID NOs: 1-12 are defined according to the Kabat numbering system.
- the antibodies of the invention are humanized antibodies.
- the present invention provides a humanized antibody or an antigen-binding fragment thereof that specifically binds CEACAM5, wherein the humanized antibody comprises a heavy chain variable region and a light chain variable region, wherein:
- the heavy chain variable region comprises the polypeptide shown in SEQ ID NO: 17 or has one or several amino acid substitutions, deletions or additions thereto (such as 1, 2 or 3 amino acid substitutions, deletions) or addition), while the light chain variable region comprises the polypeptide shown in SEQ ID NO: 18 or has one or several amino acid substitutions, deletions or additions (for example, 1, 2 or 3 amino acid substitutions, deletions or additions); or
- the heavy chain variable region comprises the polypeptide shown in SEQ ID NO: 19 or has one or several amino acid substitutions, deletions or additions thereto (such as 1, 2 or 3 amino acid substitutions, deletions) or addition), while the light chain variable region comprises the polypeptide shown in SEQ ID NO: 20 or has one or several amino acid substitutions, deletions or additions thereto (for example, 1, 2 or 3 amino acid substitutions, deletions or additions).
- substitution described in any one of the SEQ ID NO: 17-20 is a conservative substitution
- the CDRs of any one of said SEQ ID NOs: 17-20 are defined according to the Kabat numbering system.
- the present invention provides a humanized antibody or an antigen-binding fragment thereof that specifically binds CEACAM5, wherein the antibody or an antigen-binding fragment thereof comprises a constant region derived from human immunoglobulin or a variant thereof;
- the antibody or antigen-binding fragment thereof comprises:
- a heavy chain constant region (CH) of a human immunoglobulin or a variant thereof having one or more amino acid substitutions, deletions or additions or any combination thereof compared to the sequence from which it is derived e.g. , up to 20, up to 15, up to 10, or up to 5 amino acid substitutions, deletions or additions or any combination thereof; for example 1, 2, 3, 4 or 5 amino acid substitutions, deletions or added or any combination thereof; and/or
- the light chain constant region (CL) of a human immunoglobulin or a variant thereof having one or more amino acid substitutions, deletions or additions or any combination thereof compared to the sequence from which it is derived e.g. , up to 20, up to 15, up to 10, or up to 5 amino acid substitutions, deletions or additions or any combination thereof; for example 1, 2, 3, 4 or 5 amino acid substitutions, deletions or addition or any combination thereof;
- the heavy chain constant region is an IgG heavy chain constant region, such as an IgGl, IgG2, IgG3 or IgG4 heavy chain constant region;
- the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VH) shown in SEQ ID NO: 17 or SEQ ID NO: 19;
- VH heavy chain variable region
- said light chain constant region is a kappa light chain constant region
- the antibody or antigen-binding fragment thereof comprises a light chain variable region (VL) shown in SEQ ID NO: 18 or SEQ ID NO: 20.
- VL light chain variable region
- the present invention provides a humanized antibody specifically binding to CEACAM5 or an antigen-binding fragment thereof, wherein the antigen-binding fragment is selected from the group consisting of Fab, Fab', (Fab')2, Fv, disulfide bond-linked Fv, BsFv, dsFv, (dsFv)2, dsFv-dsFv', scFv, scFv dimer, camelized single chain domain antibody, diabody, ds diabody, nanobody, Single domain antibody (sdAb), bivalent domain antibody; and/or, the antibody is murine antibody, chimeric antibody, humanized antibody, bispecific antibody or multispecific antibody.
- the antigen-binding fragment is selected from the group consisting of Fab, Fab', (Fab')2, Fv, disulfide bond-linked Fv, BsFv, dsFv, (dsFv)2, dsFv-dsFv', scFv,
- the antibody or antigen-binding fragment thereof is labeled; preferably, the antibody or antigen-binding fragment thereof is labeled detectably, such as enzymes (such as horseradish peroxidase), radionuclides, fluorescent dyes , luminescent substances (such as chemiluminescent substances) or biotin.
- enzymes such as horseradish peroxidase
- radionuclides such as horseradish peroxidase
- fluorescent dyes such as fluorescent dyes
- luminescent substances such as chemiluminescent substances
- the invention provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding an antibody or antigen-binding fragment thereof that specifically binds CEACAM5.
- the invention relates to an expression vector comprising a nucleic acid molecule encoding an antibody that specifically binds CEACAM5 as disclosed herein.
- the invention relates to host cells comprising the expression vectors disclosed herein.
- the invention in another aspect, relates to a pharmaceutical composition
- a pharmaceutical composition comprising at least one antibody that specifically binds CEACAM5 disclosed herein and a pharmaceutically acceptable carrier.
- the pharmaceutical composition further comprises an additional pharmaceutically active agent;
- the additional pharmaceutically active agent is a drug with antitumor activity, such as alkylating agents, mitotic inhibitors, antitumor antibiotics, antimetabolites, topoisomerase inhibitors, tyrosine kinase inhibitors, radioactive Nuclide agents, radiosensitizers, anti-angiogenic agents, cytokines, molecularly targeted drugs, immune checkpoint inhibitors or oncolytic viruses;
- a drug with antitumor activity such as alkylating agents, mitotic inhibitors, antitumor antibiotics, antimetabolites, topoisomerase inhibitors, tyrosine kinase inhibitors, radioactive Nuclide agents, radiosensitizers, anti-angiogenic agents, cytokines, molecularly targeted drugs, immune checkpoint inhibitors or oncolytic viruses;
- said antibody or antigen-binding fragment thereof, bispecific or multispecific molecule or immunoconjugate and said additional pharmaceutically active agent are provided as separate components or as components of the same composition.
- the present invention provides a chimeric antigen receptor comprising the antigen-binding domain of the humanized antibody or an antigen-binding fragment thereof;
- the antigen-binding domain comprises the heavy chain variable region and the light chain variable region of the humanized antibody or antigen-binding fragment thereof;
- said antigen binding domain is a scFv
- said antigen-binding receptor comprises said humanized antibody or an antigen-binding fragment thereof;
- said antigen binding receptor is expressed by immune effector cells (eg T cells).
- immune effector cells eg T cells.
- the present invention provides an isolated nucleic acid molecule encoding said chimeric antigen receptor.
- the present invention provides a vector comprising the isolated nucleic acid molecule; preferably, it is used for preparing chimeric antigen receptor T cells.
- the present invention provides a host cell comprising the isolated nucleic acid molecule or the vector;
- the host cell is an immune effector cell (eg, T cell or NK cell);
- an immune effector cell eg, T cell or NK cell
- the host cell is a chimeric antigen receptor T cell (CAR-T).
- CAR-T chimeric antigen receptor T cell
- the present invention provides a method for reducing the expression level of CEACAM5 on the cell surface, which comprises combining said cells with said humanized antibody or its antigen-binding fragment, or said pharmaceutical composition, or said The chimeric antigen receptor, or the contacting of the host cell, reduces the expression level of CEACAM5 on the surface of the cell; wherein the cell expresses CEACAM5 on its surface;
- the cells are tumor cells expressing CEACAM5.
- the present invention provides a method for inhibiting the growth of tumor cells expressing CEACAM5 and/or killing the tumor cells, which comprises combining the tumor cells with an effective amount of the humanized antibody or antigen-binding fragment thereof, or the The pharmaceutical composition, or the chimeric antigen receptor, or the host cell is contacted.
- the present invention relates to a method for preparing an antibody that specifically binds CEACAM5, comprising expressing in a host cell a nucleic acid sequence encoding an antibody that specifically binds CEACAM5 as disclosed herein and isolating the specific binding antibody from the host cell.
- the present invention provides the use of the antibody of the present invention in the preparation of a medicament for treating cancers that highly express CEACAM5, wherein the cancers that highly express CEACAM5 are selected from colorectal cancer, gastric cancer, pancreatic cancer, and esophageal cancer , lung or breast cancer.
- the present invention provides a method for treating cancers that highly express CEACAM5, comprising administering the antibody of the present invention to a subject in need thereof, wherein the cancers that highly express CEACAM5 are selected from colorectal cancer, gastric cancer , pancreatic, esophageal, lung, or breast cancer.
- the subject is a mammal, such as a human;
- the method further comprises administering additional drugs with antitumor activity, such as alkylating agents, mitotic inhibitors, antitumor antibiotics, antimetabolites, topoisomerase inhibitors, tyrosine kinase inhibitors, radioactive Nuclide agents, radiosensitizers, anti-angiogenic agents, cytokines, molecularly targeted drugs, immune checkpoint inhibitors or oncolytic viruses;
- antitumor activity such as alkylating agents, mitotic inhibitors, antitumor antibiotics, antimetabolites, topoisomerase inhibitors, tyrosine kinase inhibitors, radioactive Nuclide agents, radiosensitizers, anti-angiogenic agents, cytokines, molecularly targeted drugs, immune checkpoint inhibitors or oncolytic viruses;
- the method further comprises administering an additional antineoplastic therapy, such as surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy, hormone therapy, gene therapy or palliative therapy.
- an additional antineoplastic therapy such as surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy, hormone therapy, gene therapy or palliative therapy.
- the present invention also provides an antibody-drug conjugate, which contains:
- the drug is a toxin, preferably monomethylauristatin (monomethylauristatin), calicheamicin, maytansinoids, or a combination thereof; more preferably selected from: monomethylauristatin-E ( MMAE), monomethylauristatin-D (MMAD), monomethylauristatin-F (MMAF), or a combination thereof.
- monomethylauristatin monomethylauristatin
- calicheamicin maytansinoids
- MMAF monomethylauristatin-F
- the present invention provides the use of the antibody-drug conjugate in the preparation of medicines.
- the present invention provides a bispecific antibody, which comprises a domain specifically binding to CEACAM5 and a domain specifically binding to CD3, CD28 or 41BB,
- structural domain specifically binding to CEACAM5 comprises: CDR-H1 shown in SEQ ID NO:1; CDR-H2 shown in SEQ ID NO:2, CDR-H3 shown in SEQ ID NO:3, SEQ ID NO: CDR-L1 set forth in 4, CDR-L2 set forth in SEQ ID NO:5, and CDR-L3 set forth in SEQ ID NO:6; or
- CDR-H1 shown in SEQ ID NO:7 CDR-H2 shown in SEQ ID NO:8, CDR-H3 shown in SEQ ID NO:9, CDR-L1 shown in SEQ ID NO:10, SEQ ID CDR-L2 shown in NO:11, and CDR-L3 shown in SEQ ID NO:12.
- the present invention also provides the use of the bispecific antibody in the preparation of medicines.
- Monoclonal antibodies can be prepared as follows. Injected mice or other suitable host animals are first immunized with the immunogen (adding an adjuvant if necessary).
- the immunogen or adjuvant is usually injected subcutaneously at multiple points or intraperitoneally.
- the immunogen can be pre-coupled to certain known proteins, such as serum albumin or soybean trypsin inhibitor, to enhance the immunogenicity of the antigen in the host.
- the adjuvant can be Freund's adjuvant or MPL-TDM, etc.
- lymphocytes that secrete antibodies that specifically bind to the immunogen will be produced in the body. In addition, lymphocytes can also be obtained by in vitro immunization.
- the target lymphocytes are collected and fused with myeloma cells using a suitable fusion agent, such as PEG, to obtain hybridoma cells (Goding, Monoclonal Antibodies: Principles and Practice, pp.59-103, Academic Press, 1996).
- a suitable fusion agent such as PEG
- the preferred myeloma cells should have the characteristics of high fusion rate, stable antibody secretion ability, and sensitivity to HAT medium.
- the culture medium of growing hybridoma cells is used to detect the production of monoclonal antibodies against specific antigens.
- Methods for determining the binding specificity of monoclonal antibodies produced by hybridoma cells include, for example, immunoprecipitation or in vitro binding assays, such as radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA).
- RIA radioimmunoassay
- ELISA enzyme-linked immunosorbent assay
- the affinity of mAbs can be determined using the Scatchard assay described by Munson et al., Anal. Biochem. 107:220 (1980).
- the target cell line can be limited by the criteria described in (Goding, Monoclonal Antibodies: Principles and Practice, pp.59-103, Academic Press, 1996). Subcloning by dilution.
- a suitable culture medium can be DMEM or RPMI-1640, etc.
- hybridoma cells can also be grown in animals in the form of ascites tumors.
- Monoclonal antibodies secreted by subcloned cells can be purified from cell culture fluid, isolated from ascites or serum.
- Monoclonal antibodies can also be obtained through genetic engineering and recombination techniques.
- the DNA molecules encoding the heavy chain and light chain genes of the monoclonal antibody can be isolated from hybridoma cells by using nucleic acid primers that specifically bind to the heavy chain and light chain genes of the monoclonal antibody to carry out PCR amplification. Insert the obtained DNA molecule into the expression vector, then transfect host cells (such as E.coli cells, COS cells, CHO cells, or other myeloma cells that do not produce immunoglobulin), and culture under appropriate conditions, Antibodies of interest can be obtained recombinantly expressed.
- host cells such as E.coli cells, COS cells, CHO cells, or other myeloma cells that do not produce immunoglobulin
- a tumor cell line with high expression of CEACAM5 (such as Lovo) is used to immunize mice to obtain antibodies that recognize natural CEACAM5 antigen.
- a “humanized antibody” is an antibody comprising one or both of a humanized VH domain and a humanized VL domain.
- the one or more immunoglobulin constant regions need not be present, but if present, are derived entirely or substantially from human immunoglobulin constant regions.
- Humanized antibodies are genetically engineered antibodies in which CDRs from a non-human "donor” antibody are grafted into human "recipient” antibody sequences (see, e.g., Queen, US 5,530,101 and 5,585,089; Winter, US 5,225,539; Carter, US 6,407,213; Adair, US 5,859,205; and Foote, US 6,881,557).
- the recipient antibody sequence can be, for example, a mature human antibody sequence, a complex of such sequences, a consensus sequence of human antibody sequences, or a germline sequence.
- the human acceptor sequence can be chosen such that the variable region framework has a high degree of sequence identity to the donor sequence to match typical patterns and other criteria between the acceptor and donor CDRs.
- a humanized antibody is one whose CDRs are derived wholly or substantially from the donor antibody and variable region framework sequences and whose constant regions, if present, are derived wholly or substantially from human antibody sequences.
- a humanized heavy chain typically has all three CDRs derived from the heavy chain and heavy chain variable region framework sequences of the donor antibody and substantially from human heavy chain variable region framework and constant region sequences. Chain constant region (if present).
- a humanized light chain typically has all three CDRs derived entirely or substantially from the light chain and light chain variable region framework sequences of the donor antibody and light chains substantially derived from the human light chain variable region framework and constant region sequences. Chain constant region (if present).
- the CDRs in a humanized antibody are substantially derived from the corresponding CDRs in a non-human antibody.
- variable region framework sequences of the antibody chains or the constant regions of the antibody chains, respectively are substantially derived from humans Variable region framework sequences or human constant regions.
- humanized antibodies can also be composed of fewer than all six CDRs (e.g., at least 3 CDRs) from a mouse antibody. 1, 4 or 5) CDR composition (e.g., Pascalis et al., J. Immunol. 169:3076, 2002; Vajdos et al., Journal of Molecular Biology, 320:415-428, 2002; Iwahashi et al., Mol. Immunol.36 : 1079-1091, 1999; Tamura et al., Journal of Immunology, 164: 1432-1441, 2000).
- CDR composition e.g., Pascalis et al., J. Immunol. 169:3076, 2002; Vajdos et al., Journal of Molecular Biology, 320:415-428, 2002; Iwahashi et al., Mol. Immunol.36 : 1079-1091, 1999; Tamura et al., Journal of Immunology, 164: 1432-1441, 2000).
- a CDR in a humanized antibody is "substantially from the corresponding CDRs in a non-human antibody.
- the CDRs of the humanized VH or VL domain span all three CDRs with respect to the corresponding non-human VH or VL CDRs. No more than six (eg, no more than five, no more than four, no more than three, no more than two, or no more than one) amino acid substitutions (preferably conservative substitutions).
- variable region framework sequences of antibody VH or VL domains or immunoglobulin constant region are "substantially derived from" human VH or VL framework sequences or human constant regions, respectively.
- all portions of a humanized antibody, except the CDRs will usually be derived wholly or substantially from corresponding portions of native human immunoglobulin sequences.
- antibody refers to an immunoglobulin molecule, usually composed of two pairs of polypeptide chains, each pair having one light chain and one heavy chain.
- Antibody light chains can be classified as kappa and lambda light chains.
- Heavy chains can be classified as mu, delta, gamma, alpha, or epsilon, and define the antibody's isotype as IgM, IgD, IgG, IgA, and IgE, respectively.
- the variable and constant regions are joined by a "J" region of about 12 or more amino acids, with the heavy chain also comprising a "D" region of about 3 or more amino acids.
- Each heavy chain is composed of a heavy chain variable region (VH) and a heavy chain constant region (CH).
- the heavy chain constant region consists of 3 domains (CH1, CH2 and CH3).
- Each light chain is composed of a light chain variable region (VL) and a light chain constant region (CL).
- the light chain constant region consists of one domain, CL.
- the constant regions of the antibodies mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (eg, effector cells) and the first component (Clq) of the classical complement system.
- the VH and VL regions can also be subdivided into regions of high variability called complementarity determining regions (CDRs) interspersed with more conserved regions called framework regions (FRs).
- CDRs complementarity determining regions
- Each VH and VL consists of 3 CDRs and 4 FRs arranged in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4, from amino-terminus to carboxy-terminus.
- the variable regions (VH and VL) of each heavy chain/light chain pair form the antibody binding site, respectively. Assignment of amino acids to regions or domains follows the Kabat Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md. (1987and 1991)), or Chothia & Lesk (1987) J.Mol.Biol.196:901-917; Definition by Chothia et al. (1989) Nature 342:878-883.
- antibody is not limited to any particular method of producing antibodies. For example, it includes recombinant antibodies, monoclonal antibodies and polyclonal antibodies. Antibodies can be of different isotypes, eg, IgG (eg, IgGl, IgG2, IgG3, or IgG4 subtype), IgAl, IgA2, IgD, IgE, or IgM antibodies.
- IgG eg, IgGl, IgG2, IgG3, or IgG4 subtype
- IgAl IgA2, IgD, IgE, or IgM antibodies.
- antibody when the term “antibody” is referred to, it includes not only whole antibodies but also antigen-binding fragments of antibodies.
- antigen-binding fragment of an antibody refers to a polypeptide comprising a fragment of a full-length antibody that retains the ability to specifically bind to the same antigen to which the full-length antibody binds, and/or competes with the full-length antibody for Specific binding to an antigen, which is also referred to as an "antigen-binding moiety". See generally, Fundamental Immunology, Ch.7 (Paul, W., ed., 2nd ed., Raven Press, N.Y.
- antigen-binding fragments include Fab, Fab', F(ab')2, Fd, Fv, dAb, and complementarity determining regions (CDRs) Fragments, single chain antibodies (eg, scFv), chimeric antibodies, diabodies, and polypeptides comprising at least a portion of an antibody sufficient to confer specific antigen-binding ability to the polypeptide.
- Antigen-binding fragments of antibodies can be obtained from a given antibody using conventional techniques known to those of skill in the art (e.g., recombinant DNA techniques or enzymatic or chemical fragmentation methods), and can be used in the same way as for the intact Antigen-binding fragments of antibodies are screened for specificity in the same manner as antibodies.
- mAb and “monoclonal antibody” refer to an antibody or a fragment of an antibody derived from a population of highly homogeneous antibody molecules, that is, excluding natural mutations that may occur spontaneously , a group of identical antibody molecules. mAbs are highly specific for a single epitope on an antigen. Compared with monoclonal antibodies, polyclonal antibodies usually contain at least two or more different antibodies, and these different antibodies usually recognize different epitopes on antigens. Monoclonal antibodies can usually be obtained using hybridoma technology first reported by Kohler et al. (Nature, 256:495, 1975), but can also be obtained using recombinant DNA technology (see, for example, U.S.P 4,816,567).
- monoclonal antibodies can be prepared as follows. Injected mice or other suitable host animals are first immunized with the immunogen (adding an adjuvant if necessary).
- the immunogen or adjuvant is usually injected subcutaneously at multiple points or intraperitoneally.
- the immunogen can be pre-coupled to certain known proteins, such as serum albumin or soybean trypsin inhibitor, to enhance the immunogenicity of the antigen in the host.
- the adjuvant can be Freund's adjuvant or MPL-TDM, etc.
- lymphocytes that secrete antibodies that specifically bind to the immunogen will be produced in the body.
- lymphocytes can also be obtained by in vitro immunization.
- the target lymphocytes are collected and fused with myeloma cells using a suitable fusion agent, such as PEG, to obtain hybridoma cells (Goding, Monoclonal Antibodies: Principles and Practice, pp.59-103, Academic Press, 1996).
- a suitable fusion agent such as PEG
- the hybridoma cells prepared above can be inoculated to grow in a suitable culture medium, which preferably contains one or more substances capable of inhibiting the growth of unfused, parental myeloma cells.
- HGPRT hypoxanthine guanine phosphotransferase
- adding substances such as hypoxanthine, aminopterin, and thymine (HAT medium) to the culture medium will inhibit HGPRT- Defective cell growth.
- HAT medium hypoxanthine, aminopterin, and thymine
- the preferred myeloma cells should have the characteristics of high fusion rate, stable antibody secretion ability, and sensitivity to HAT medium.
- murine myeloma is the first choice for myeloma cells, such as MOP-21 or MC-11 mouse tumor derivative strain (THE Salk Institute Cell Distribution Center, San Diego, Calif.
- Methods for determining the binding specificity of monoclonal antibodies produced by hybridoma cells include, for example, immunoprecipitation or in vitro binding assays, such as radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA).
- RIA radioimmunoassay
- ELISA enzyme-linked immunosorbent assay
- the affinity of mAbs can be determined using the Scatchard assay described by Munson et al., Anal. Biochem. 107:220 (1980).
- the target cell line can be limited by the criteria described in (Goding, Monoclonal Antibodies: Principles and Practice, pp.59-103, Academic Press, 1996). Subcloning by dilution.
- a suitable culture medium can be DMEM or RPMI-1640, etc.
- hybridoma cells can be grown in animals in the form of ascites tumors.
- Monoclonal antibodies secreted by subcloned cells can be purified from cell culture fluid, isolated from ascites or serum.
- Monoclonal antibodies can also be obtained through genetic engineering and recombination techniques.
- the DNA molecules encoding the heavy chain and light chain genes of the monoclonal antibody can be isolated from hybridoma cells by using nucleic acid primers that specifically bind to the heavy chain and light chain genes of the monoclonal antibody to carry out PCR amplification. Insert the obtained DNA molecule into the expression vector, then transfect host cells (such as E.coli cells, COS cells, CHO cells, or other myeloma cells that do not produce immunoglobulin), and culture under appropriate conditions, Antibodies of interest can be obtained recombinantly expressed.
- host cells such as E.coli cells, COS cells, CHO cells, or other myeloma cells that do not produce immunoglobulin
- chimeric antibody refers to an antibody whose light chain and/or heavy chain are partially derived from one antibody (which may be derived from a specific species or belong to a specific antibody class or subclass), and the other part of the light chain or/and heavy chain is derived from another antibody (which may be derived from the same or different species or belong to the same or different antibody class or subclass), but in any case, it still retains Binding activity to target antigen (U.S.P 4,816,567to Cabilly et al.; Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851 6855 (1984)).
- human antibody refers to a humanized antibody in which all or part of the CDR regions of a human immunoglobulin (recipient antibody) are replaced by the CDR regions of a non-human antibody (donor antibody)
- the donor antibody may be a non-human (for example, mouse, rat or rabbit) antibody with desired specificity, affinity or reactivity.
- some amino acid residues in the framework region (FR) of the acceptor antibody can also be replaced by amino acid residues of corresponding non-human antibodies, or by amino acid residues of other antibodies, so as to further improve or optimize the performance of the antibody.
- epitope refers to a site on an antigen that is specifically bound by an immunoglobulin or an antibody.
- An “epitope” is also referred to in the art as an "antigenic determinant”.
- Epitopes or antigenic determinants usually consist of chemically active surface groups of molecules such as amino acids or carbohydrate or sugar side chains, and usually have specific three-dimensional structural characteristics as well as specific charge characteristics.
- an epitope typically includes at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 consecutive or non-contiguous amino acids in a unique spatial conformation, which may be "linear of” or “conformational”. See, eg, Epitope Mapping Protocols in Methods in Molecular Biology, Vol.
- epitope peptide refers to a peptide segment on an antigen that can serve as an epitope.
- an epitope peptide alone is capable of being specifically recognized/bound by an antibody directed against the epitope.
- carrier protein refers to a protein that can act as a carrier for an epitope peptide, i.e., it can insert an epitope peptide at a specific position (e.g., inside the protein, N-terminal or C-terminal) , so that the epitope peptide can be presented, so that the epitope peptide can be recognized by antibodies or the immune system.
- carrier proteins are well known to those skilled in the art and include, for example, the HPV L1 protein (epitope peptides may be inserted between amino acids 130-131 or between amino acids 426-427 of the protein, see Slupetzky ,K.
- HBV core antigen the 79th part of the protein can be replaced with an epitope peptide -81 amino acid, see Koletzki, D., et al.HBV core particles allow the insertion and surface exposure of the entire potentially protective region of Puumala hantavirus nucleocapsid protein[J].Biol Chem,1999,380:325-333), Woodchuck hepatitis virus core protein (amino acids 79-81 of the protein can be replaced with epitope peptides, see Sab
- CRM197 protein epitope peptides can be linked to the N- or C-terminus of the protein or fragments thereof.
- a linker eg, a flexible or rigid linker
- the epitope peptide and the carrier protein can be used to facilitate folding of both.
- Antibodies can be competitively screened for binding to the same epitope using routine techniques known to those of skill in the art. For example, competition and cross-competition studies can be performed to obtain antibodies that compete with each other or cross-compete for binding to an antigen (eg, influenza virus hemagglutinin protein). A high-throughput method to obtain antibodies binding to the same epitope based on their cross-competition is described in International Patent Application WO 03/48731. Thus, antibodies and antigen-binding fragments thereof (ie, antigen-binding portions) that compete with the monoclonal antibodies of the invention for binding to the same epitope on the influenza virus hemagglutinin protein can be obtained using routine techniques known to those skilled in the art.
- an antigen eg, influenza virus hemagglutinin protein
- an antibody that specifically binds to an antigen refers to an antibody that is less than about 10 -5 M, such as less than about 10 -6 M, 10 -7 M, Binds the antigen with an affinity (K D ) of 10 ⁇ 8 M, 10 ⁇ 9 M or 10 ⁇ 10 M or less.
- KD refers to the dissociation equilibrium constant for a particular antibody-antigen interaction, which is used to describe the binding affinity between an antibody and antigen.
- Figure 1 shows the binding results of recombinant chimeric antibody to CEACAM5 recombinant protein.
- Figure 2 shows the binding of recombinant chimeric antibody to CEACAM5 domain.
- Figure 3 shows the binding of recombinant chimeric antibody to LS174T cells and KATO3 cells highly expressing CEACAM5.
- Figure 4 shows the binding of humanized antibodies to recombinant CEACAM5 antigen.
- Figure 5 shows the binding of humanized antibody pairs to LS174T cells highly expressing CEACAM5.
- SEQ ID NO: describe 1 M22 heavy chain variable region CDR1 2 M22 heavy chain variable region CDR2 3 M22 heavy chain variable region CDR3 4 M22 light chain variable region CDR1 5 M22 light chain variable region CDR2 6 M22 light chain variable region CDR3 7 M25 heavy chain variable region CDR1 8 M25 heavy chain variable region CDR2 9 M25 heavy chain variable region CDR3 10 M25 light chain variable region CDR1 11 M25 light chain variable region CDR2 12 M25 light chain variable region CDR3 13 M22 heavy chain variable region 14 M22 light chain variable region
- a tumor cell line expressing CEACAM5 was used to immunize mice to prepare monoclonal antibodies.
- the Lovo cell line ATCC CCL-229 which highly expresses CEACAM5
- Anti-CEACAM5 antibody hMN14 (Immunomedics, Phase 2 drug) was used to Lovo cells, expressed through recombinant, the sequence is as follows
- the Lovo 6-1 clone was knocked out of the CEACAM5 gene by the CRISPR method, and the Lovo CEACAM5 KO cell line (hereinafter referred to as the Lovo CEA KO cell line) was screened.
- the vector carrying CRISPR and sgRNA was packaged into a lentiviral vector (CEACAM5 KO1-3), and transduced into Lovo 6-1 cells. After transduction, CEACAM5 expression (MN14 antibody) was detected by FACS, and MN14 binding was detected by mouse Fc-APC secondary antibody .
- the results showed that CEACAM5 KO1-3 could knock out CEACAM5, and the knockout efficiency of CEACAM5 KO3 carrier was higher, and the negative population of CEACAM5 was clearer.
- the sequences of the three sgRNAs targeting CEACAM5 are as follows:
- Lovo cells and Lovo CEA KO cells at 10 4 per well in a 96-well plate for overnight culture, add 1-10 ⁇ l of the hybridoma supernatant to the Lovo/Lovo CEA KO cell culture plate, incubate for 1 hour, and discard the supernatant
- Add anti-mouse Fc-FITC fluorescent secondary antibody after incubation for 1 hour, discard the supernatant, add DPBS solution containing 2% BSA, read and analyze the fluorescent signal and FITC staining area in Celigo.
- the picked hybridoma clones were subjected to hybridoma sequencing according to a standard hybridoma sequencing method to obtain the heavy chain and light chain variable regions (VH and VL) of the picked clones.
- VH and VL were synthesized by whole gene synthesis and linked to the human IgG1 and kappa chain constant regions, and the heavy chain and light chain sequences were linked to the pcDNA3.4 vector for transient expression in the 293 system and protein A/G purification.
- the resulting chimeric recombinant antibody was subjected to ultrafiltration for buffer replacement with PBS solution.
- the sequencing results are shown in the table below.
- the CEACAM5 molecule was split according to its extracellular domain (A1-B1-A2-B2-A3-B3), and A1-B1-His Tag, A2-B2-His Tag, and A3-B3-His Tag were respectively constructed for expression Vector, and after being expressed in the 293 system, it was purified using a Ni column, and the sequence is shown in the table below:
- LS174T cells and KATO3 cells were cultured in RPMI1640 medium containing 10% FBS. After the cells were digested with trypsin, they were centrifuged and resuspended in DPBS solution (FACS buffer, 4 °C) containing 2% BSA.
- DPBS solution FACS buffer, 4 °C
- CEA family Gene ID mRNA sequence CEACAM1 634 NM_001712.5 CEACAM3 1084 NM_001815.5 CEACAM5 1048 NM_004363.6 CEACAM6 4680 NM_002483.7 CEACAM8 1088 NM_001816.4
- cM22hIgG1 and cM25hIgG1 antibodies to the above cells at a final concentration of 5ug/ml, namely RKO, RKO-CEA1, RKO-CEA3, RKO-CEA5, RKO-CEA6, RKO-CEA8, and perform cell binding FACS determination.
- the positive percentage of antibody binding to the corresponding cell line the result is as follows:
- VH and VL regions of the above antibodies were linked to the human IgG1 Fc region and the kappa constant region, and the heavy and light chain sequences of the antibody were inserted into the pcDNA3.4 vector, transiently expressed in 293 cells, and purified by protein A or G.
- LS174T cells (high expression of CEACAM5; ATCC, CL-188) were cultured in RPMI1640 medium containing 10% FBS, digested with trypsin, centrifuged and resuspended in DPBS solution containing 2% BSA (FACS buffer, 4°C ), add 5 ⁇ 10 5 /100 ⁇ l/well into a U-bottom 96-well plate, and add antibody diluted in a gradient concentration, incubate at 4°C for 1 hour, discard the supernatant after centrifugation; add 100 ⁇ l containing anti-human IgG Fc-APC secondary antibody was incubated at 4°C for 1 hour, washed once with FACS buffer, resuspended in 200 ⁇ l FACS buffer, and the fluorescence signal value was read on BD CantoII. The result is shown in Figure 5.
- hM22.9hIgG1, hM25.6hIgG1, hAb796hIgG1, hPR1A3hIgG1, and hIgG Ctrl were dye-labeled with pHAb amino-conjugated dyes (labeled antibodies are endocytosed in a low-pH environment, and excitation light at 532nm and 560nm can detect excitation fluorescence).
- pHAb amino-conjugated dyes labeled antibodies are endocytosed in a low-pH environment, and excitation light at 532nm and 560nm can detect excitation fluorescence.
- Add the above antibody to MKN45 cells to a final concentration of 10 ⁇ g/ml, and incubate at 37°C for 24 hours. After the cells are washed, read the fluorescence value of the PE channel to detect the endocytosis of the labeled antibody.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La présente invention concerne un anticorps spécifiquement lié à CEACAM5, la préparation d'un anticorps humanisé associé et son utilisation.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110697514.7 | 2021-06-23 | ||
CN202110697514.7A CN115505043A (zh) | 2021-06-23 | 2021-06-23 | 特异性结合糖基化ceacam5的抗体 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022267936A1 true WO2022267936A1 (fr) | 2022-12-29 |
Family
ID=84499345
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/098746 WO2022267936A1 (fr) | 2021-06-23 | 2022-06-14 | Anticorps spécifiquement lié à ceacam5 glycosylé |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN115505043A (fr) |
WO (1) | WO2022267936A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116178556B (zh) * | 2023-01-09 | 2024-01-09 | 南方医科大学第三附属医院(广东省骨科研究院) | 靶向ceacam5的纳米抗体及其制备方法与应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020244528A1 (fr) * | 2019-06-04 | 2020-12-10 | 上海吉倍生物技术有限公司 | Anticorps monoclonal anti-ceacam5, son procédé de préparation et son utilisation |
-
2021
- 2021-06-23 CN CN202110697514.7A patent/CN115505043A/zh active Pending
-
2022
- 2022-06-14 WO PCT/CN2022/098746 patent/WO2022267936A1/fr active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020244528A1 (fr) * | 2019-06-04 | 2020-12-10 | 上海吉倍生物技术有限公司 | Anticorps monoclonal anti-ceacam5, son procédé de préparation et son utilisation |
Also Published As
Publication number | Publication date |
---|---|
CN115505043A (zh) | 2022-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6783886B2 (ja) | 抗ctla4モノクローナル抗体またはその抗原結合断片、医薬組成物および使用 | |
CN106519034B (zh) | 抗pd-1抗体及其用途 | |
WO2017148424A1 (fr) | Anticorps anti-pdl-1, composition pharmaceutique et utilisations de celui-ci | |
CN111454357B (zh) | 一种含有抗体的肿瘤治疗剂的开发和应用 | |
WO2021058000A1 (fr) | Anticorps anti-claudine 18,2 humaine et son application | |
EP3645741A2 (fr) | Anticorps anti-4-1bb et leurs procédés de préparation et d'utilisation | |
EP4039704A1 (fr) | Anticorps anti-pd-1 et son utilisation | |
WO2023151693A1 (fr) | Composition pharmaceutique comprenant un anticorps anti-tigit et un anticorps bispécifique anti-pd-1-anti-vegfa, et utilisation | |
CN113321734A (zh) | 抗cd47/抗pd-l1抗体及其应用 | |
WO2022007543A1 (fr) | Anticorps anti-fgl1 et son utilisation | |
WO2021098822A1 (fr) | Anticorps bispécifiques | |
TW202221041A (zh) | 一種結合人pd-l1的抗體 | |
CN107108734B (zh) | 单克隆抗gpc-1抗体和其用途 | |
WO2022089392A1 (fr) | Anticorps anti-tigit, composition pharmaceutique et utilisation correspondante | |
WO2022267936A1 (fr) | Anticorps spécifiquement lié à ceacam5 glycosylé | |
CN114667296B (zh) | 一种双特异性抗体及其用途 | |
CN115838424A (zh) | 靶向tigit的单克隆抗体 | |
JP7392200B2 (ja) | グリコシル化ceacam5に特異的に結合した抗体 | |
TWI804099B (zh) | 特異性結合糖基化ceacam5的抗體及其製備方法 | |
WO2023186081A1 (fr) | Anticorps bispécifique anti-tigit/anti-pvrig, composition pharmaceutique et utilisation associées | |
WO2023025306A1 (fr) | Anticorps bispécifique ciblant pd-l1 et cldn18.2, son procédé de préparation et son utilisation | |
WO2023186063A1 (fr) | Anticorps anti-pvrig, composition pharmaceutique et utilisation associées | |
TWI845767B (zh) | 抗人Claudin18.2抗體及其應用 | |
WO2023001303A1 (fr) | Composition pharmaceutique et son utilisation | |
WO2024094003A1 (fr) | Anticorps anti-ccr8 et son utilisation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22827432 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22827432 Country of ref document: EP Kind code of ref document: A1 |